drugset / Trial / NCT01055041

Controller Medications in the Management of Bronchial Asthma

NCT01055041

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to know the effect of another controller medication add on to the inhaled corticosteroid and long acting β2 agonist on clinical symptom, lung function and compliance in patients of moderate to severe persistent bronchial asthma.

Timeline

Start
2008-12
Primary completion
2009-06
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 200 ug Inhaled
Subject Doxofylline Small molecule 400 mg Oral
Subject Montelukast Other / unclassified 10 mg Oral
Background formeterol Unknown 6 ug Inhaled

Indications